ArticleClinicoEconomics and outcomes research : CEOR2026
Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the cost-effectiveness of nivolumab plus doxorubicin/vinblastine/dacarbazine (N-AVD) versus brentuximab vedotin-AVD (BV-AVD) as first-line treatment for advanced-stage classical Hodgkin lymphoma. Design: Cost-effectiveness analysis using a Markov model based on the S1826 trial (n=970). We estimated total direct costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER). Sensitivity analyses assessed robustness. Results: Nivolumab-AVD yielded 6.560 QALYs and 15.659 LYs, representing gains of 0.504 QALYs and 0.551 LYs over Brentuximab vedotin-AVD. Total costs were $784,839 for Nivolumab-AVD compared with $789,205 for Brentuximab vedotin-AVD. Nivolumab-AVD was associated with negative incremental cost-effectiveness ratios (-$8,656 per QALY; -$7,926 per LY) and was dominant, offering superior health outcomes at a lower overall cost. Conclusion: From a Chinese healthcare payer perspective, nivolumab-AVD is more cost-effective than brentuximab vedotin-AVD for advanced-stage classical Hodgkin lymphoma, offering lower costs and better health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.